SBIR-STTR Award

Evaluating Novel Multi-Kinase Peptide Inhibitors as a Treatment for Rheumatoid AR
Award last edited on: 8/8/23

Sponsored Program
SBIR
Awarding Agency
NIH : NCCAM
Total Award Amount
$217,059
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
David Men-Hwei Tsai

Company Information

Ambrx Inc (AKA: Ambryx Biotechnology Inc)

10975 North Torrey Pines Road
San Diego, CA 92037
   (858) 875-2400
   info@ambrx.com
   www.ambrx.com
Location: Single
Congr. District: 50
County: San Diego

Phase I

Contract Number: 1R43AT007736-01A1
Start Date: 9/30/13    Completed: 3/31/15
Phase I year
2013
Phase I Amount
$217,059
Cancer and rheumatoid arthritis (RA) share remarkably similar pathogenic pathways. For example, in both cancer and RA, angiogenesis, chronic inflammation and reactive oxygen species create a negative feedback loop that accelerates disease progression. In the synovium of RA patients, fibroblast-like synoviocytes (RA- FLS) has features of tumor-like transformation including anchorage-independent growth, adhesion to the extracellular matrix of cartilage, resistance to apoptotic signaling, and invasiveness to cartilage and bone. We have isolated a novel milk peptide mixture (AX-3) that inhibits the tyrosine kinase activity of epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor 2 (VEGFR2), and insulin receptor (IR). In vivo, AX-3 exhibits anti-cancer activity, increases the level of antioxidant enzyme Superoxide Dismutase, and reduces pro-inflammatory factors TNF-alpha, MCP-1, and RANTES. Recently, we further identified the active component of AX-3. These recent data and the understanding that inflammation, angiogenesis, hyperplasia, and oxidative stress are crucial mediators of RA led us to investigate the potential of AX-3 and its active component as therapeutic candidates for treating rheumatoid arthritis. In Specific Aim 1, AX-3 and its active component will be tested for their ability to induce apoptosis in RA-FLS. At lower dosages, the peptides will be assessed for inhibition of pro-inflammatory factor expressions in RA-FLS, and inhibition of several signaling pathways will also be tested. In Specific Aim 2, the in vivo effects of AX-3 and its active component on joint degradation and various biomarkers will be assessed using a collagen- induced RA rat model. In phase II study we will continue further molecular characterization and pharmacological studies based on the preliminary in vitro and animal results. The long term goal of this project is to develop a safe, effective, and cost-efficient therapy to treat RA.

Public Health Relevance Statement:


Public Health Relevance:
Rheumatoid arthritis (RA) is an autoimmune joint disease that affects approximately 1% of the population. In addition to disability and decreased quality of life RA decreases life expectancy, most commonly from accelerated atherosclerosis. This study will investigate the feasibility of a milk-based substance's ability to slow the progression of RA by reducing inflammation and cartilage breakdown.

NIH Spending Category:
Arthritis; Autoimmune Disease; Complementary and Alternative Medicine

Project Terms:
Adhesions; Affect; alpha Lactalbumin; Anchorage-Independent Growth; angiogenesis; Animal Model; Animals; Ankle; Antihypertensive Agents; antimicrobial; Antioxidants; Apoptosis; Apoptotic; arthropathies; Atherosclerosis; Autoimmune Process; base; BCL2 gene; Binding (Molecular Function); Biological Assay; Biological Markers; bone; Bone Matrix; Bone Resorption; Cancer Patient; Cartilage; caspase-3; Cattle; CCL2 gene; Cell Survival; Chronic; Clinical; Collagen; cost effective; cytokine; Data; Deposition; disability; Disease; Disease Progression; dosage; EGFR Protein Overexpression; Enzyme-Linked Immunosorbent Assay; Enzymes; Epidermal Growth Factor Receptor; Evaluation; Exhibits; Extracellular Matrix; Feedback; Fibroblasts; Goals; Growth Factor; Human; human TNF protein; Hyperplasia; I-kappa B Proteins; IL8 gene; In Vitro; in vivo; Inflammation; Inflammatory; inhibitor/antagonist; Insulin Receptor; Interleukin-1; Interleukin-6; Joints; Knee; Lesion; Life Expectancy; Lymphocyte; Macrophage Inflammatory Protein-1; Malignant Neoplasms; MAPK14 gene; MAPK8 gene; Mediator of activation protein; Milk; Milk Proteins; Modeling; Modification; Molecular; neutrophil; novel; oxidation; Oxidative Stress; Pathologic Processes; Pathway interactions; Patients; Peptides; phase 1 study; phase 2 study; Phosphotransferases; Play; Population; Production; Property; Protein Tyrosine Kinase; Proto-Oncogene Proteins c-akt; public health relevance; Quality of life; RANTES; Rattus; Reactive Oxygen Species; Research; research study; Resistance; Rheumatoid Arthritis; Role; Serum; Signal Pathway; Signal Transduction; Signaling Molecule; Superoxide Dismutase; Synovial Fluid; Synovial Membrane; TdT-Mediated dUTP Nick End Labeling Assay; Testing; Therapeutic; TNF gene; tumor; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor Receptor; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors; Western Blotting; Zinc

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----